Reyataz - Bristol-myers
These patents cover the drug REYATAZ. It is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS).
- The Winner is guaranteed a minimum amount ($2,000 for a $4,500 Study). The Winner receives a $500 bonus for a winning NPL or Chinese/Japanese patent, and an additional $500 if the winning NPL is non-English.
- Two (2) CrowdSearch Experts will receive $500 each.
- Up to five (5) MVRs will receive $100 each.
Please complete the eligibility questionnaire below. The questions apply to the study patent and each reference you submit for this study.
The active ingredient of REYATAZ is atazanavir sulfate.
The patents relate to the structure, compositions, formulations and methods of use of atazanavir sulfate.
Name of Substance
2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester,
(3S,8S,9S,12S)-2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3S-(3R*,8R*,9R*,12R*))-
In allowing the claims of the â€˜911 patent, the examiner wrote:
â€œClaims 1-11 are allowed. The closest prior art is Fassler et al. (J. Med. Chem. 1996, vol. 39, pages 3203-3216) disclose aza-peptide analogs as potent Human Immunodeficiency Virus Type-1 Protease Inhibitors with oral bioavailability.
The instant claims differ from the reference in having the substituted phenyl group at R4 position, whereas the reference teach [sic] unsubstituted phenyl group at the same position. This difference was neither taught or suggested by the prior art of record.â€
See the claims in the downloadable copies of the patents.
All submissions must be made by 12 Noon ET on the Study Close Date. You may submit up to the submission limit indicated on your Activity Dashboard. Your submission limit for the Study may be increased based on the quality of your previous submissions for the same Study.
Highlights: When prompted by the submission form, you must highlight the most important parts of your submission in the fields provided. The submission may not be eligible for Rewards if the citations or highlights are incomplete or insufficient.
Translations: A non-English submission must include an English translation of at least the highlighted section. If the reference appears to be relevant, a Reviewer may contact you for an extended translation.
CS Experts: All Experts assigned to this CrowdSearch Study must submit the Expert Questionnaire twice. The first Questionnaire is due on Day 10 of the Study, and the second Questionnaire is due during Week 5 or at the completion of the Study. If the Questionnaires are not submitted, the Expert may risk losing the Reward. Study participants not assigned as Experts are not asked to submit the Questionnaire.
The Researcher Agreement and all other eligibility requirements apply. Submissions may not be shared with other Researchers.
Please refer to our FAQ portal if you have any general questions. Feel free to contact AOP Support at firstname.lastname@example.org if you need further information. AOP Support is available Monday-Friday between 9 AM - 5 PM ET. Please allow up to 48 hours for a response as we gather the most accurate information to address your query.
Become a Researcher
To date, Article One has paid out $7,689,182 to the Researchers.
Choose your work
Select research projects that suit your personal preferences.
Receive monetary compensation for submitting high-quality research.
Learn while you earn
Explore new tech areas as you develop your research skills.